US Patent 12076321 (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone citrate
Patent 12076321 was granted and assigned to Centrexion Therapeutics on September, 2024 by the United States Patent and Trademark Office.
Is a
Current Assignee
Date Filed
October 13, 2021
0
Date of Patent
September 3, 2024
0
Patent Applicant
Patent Application Number
17500367
0
Patent Citations
•••
Patent Inventor Names
Ulrike Werthmann
0
Markus Ostermeier
0
Patent Jurisdiction
Patent Number
Patent Primary Examiner
Find more entities like US Patent 12076321 (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone citrate
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
